Summary of results according to larger studies analyzing the outcome after myeloablative allogeneic stem cell transplantation in CLL
Study . | No. patients . | Refractory patients, % . | Characteristics of the study . | NRM, % . | Relapse risk, % (year of projection) . | PFS, % (year of projection) . | OS, % (year of projection) . |
|---|---|---|---|---|---|---|---|
| Pavletic et al (Omaha, 2000)80 | 23 | 61 | Single-center series | 30 | 2 (5) | 62 (5) | 65 (5) |
| Michallet et al (EBMT, 2000)81 | 209 | 44 | Registry study | 40 | 25 (3) | NR | 55 (3) |
| Horowitz et al (IBMTR, 2000)82 | 242 | 50 | Registry study | 30 | 25 (3) | 44 (3) | 45 (3) |
| Khouri et al (MDACC, 2002)83 | 28 | 68 | Single-center series | NA | NA | 26 (5)* | 31 (5)* |
| Doney et al (Seattle, 2002)84 | 25 | 64 | Single-center series | 40 | < 10 | NR | 32 (5) |
| Esteve et al (International series, 2001)85 | 46 | 55 | Multicenter study | 41 | 18 (5) | 51 (5) | 58 (5) |
| Michallet et al (EBMT/IBMTR, 2003)86 | 54 | NR | Registry study | 46 | NR | 37 (10) | 41 (10) |
| Esteve et al (Hospital Clinic, 2005)87 | 17 | 35 | Single-center series | 24 | 9 (6) | 66 (6) | 76 (6) |
| Pavletic et al (NMDP, 2005)88 | 38 | 55 | Unrelated donor registry study | 38 | 32 (5) | 30 (5) | 33 (5) |
| Gribben et al (Dana-Farber, 2005)89 | 27 | 0 | Single-center series | 27 | 68 (6) | 24 (6) | 58 (6) |
Study . | No. patients . | Refractory patients, % . | Characteristics of the study . | NRM, % . | Relapse risk, % (year of projection) . | PFS, % (year of projection) . | OS, % (year of projection) . |
|---|---|---|---|---|---|---|---|
| Pavletic et al (Omaha, 2000)80 | 23 | 61 | Single-center series | 30 | 2 (5) | 62 (5) | 65 (5) |
| Michallet et al (EBMT, 2000)81 | 209 | 44 | Registry study | 40 | 25 (3) | NR | 55 (3) |
| Horowitz et al (IBMTR, 2000)82 | 242 | 50 | Registry study | 30 | 25 (3) | 44 (3) | 45 (3) |
| Khouri et al (MDACC, 2002)83 | 28 | 68 | Single-center series | NA | NA | 26 (5)* | 31 (5)* |
| Doney et al (Seattle, 2002)84 | 25 | 64 | Single-center series | 40 | < 10 | NR | 32 (5) |
| Esteve et al (International series, 2001)85 | 46 | 55 | Multicenter study | 41 | 18 (5) | 51 (5) | 58 (5) |
| Michallet et al (EBMT/IBMTR, 2003)86 | 54 | NR | Registry study | 46 | NR | 37 (10) | 41 (10) |
| Esteve et al (Hospital Clinic, 2005)87 | 17 | 35 | Single-center series | 24 | 9 (6) | 66 (6) | 76 (6) |
| Pavletic et al (NMDP, 2005)88 | 38 | 55 | Unrelated donor registry study | 38 | 32 (5) | 30 (5) | 33 (5) |
| Gribben et al (Dana-Farber, 2005)89 | 27 | 0 | Single-center series | 27 | 68 (6) | 24 (6) | 58 (6) |
NRM indicates nonrelapse mortality; PFS, progression-free survival; OS, overall survival; NR, not reported; IBMTR, International Bone Marrow Transplant Registry; MDACC, MD Anderson Cancer Center at Houston; NA, not available; and NMDP, National Marrow Donor Program.
Referred to the subset of refractory patients